52 related articles for article (PubMed ID: 32801282)
1. Risk Factors for Skin Toxicities Associated with Bendamustine-Based Chemotherapy in Patients with Non-Hodgkin Lymphoma.
Uchida M; Mori Y; Akiba K; Miyasaka M; Hirano T; Ikesue H; Yamaguchi Y; Takano A; Maegawa N; Shimomura Y; Hosohata K; Muroi N; Ishikawa T; Hashida T; Nakamura T
Biol Pharm Bull; 2020 Oct; 43(10):1577-1582. PubMed ID: 32801282
[TBL] [Abstract][Full Text] [Related]
2. Pegfilgrastim in primary prophylaxis of febrile neutropenia following frontline bendamustine plus rituximab treatment in patients with indolent non-Hodgkin lymphoma: a single center, real-life experience.
Cerchione C; De Renzo A; Di Perna M; Della Pepa R; Pugliese N; Catalano L; Pane F; Picardi M
Support Care Cancer; 2017 Mar; 25(3):839-845. PubMed ID: 27812763
[TBL] [Abstract][Full Text] [Related]
3. Increased Risk of Infectious Complications in Older Patients With Indolent Non-Hodgkin Lymphoma Exposed to Bendamustine.
Fung M; Jacobsen E; Freedman A; Prestes D; Farmakiotis D; Gu X; Nguyen PL; Koo S
Clin Infect Dis; 2019 Jan; 68(2):247-255. PubMed ID: 29800121
[TBL] [Abstract][Full Text] [Related]
4. Bendamustine-based therapy as first-line treatment for non-Hodgkin lymphoma.
Gil L; Kazmierczak M; Kroll-Balcerzak R; Komarnicki M
Med Oncol; 2014 May; 31(5):944. PubMed ID: 24752517
[TBL] [Abstract][Full Text] [Related]
5. The impact of CHOP versus bendamustine on bone mineral density in patients with indolent lymphoma enrolled in the GALLIUM study.
Pedersen MA; Gormsen LC; Jakobsen LH; Eyre TA; Severinsen MT; Baech J; Dann EJ; Knapp A; Sahin D; Vestergaard P; El-Galaly TC; Jensen P
Br J Haematol; 2024 Apr; 204(4):1271-1278. PubMed ID: 37957542
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and safety of bendamustine in the BEABOVP regimen for the treatment of pediatric patients with Hodgkin lymphoma.
Purvis KN; Swanson HD; Niloy KK; Zhou Y; Panetta JC; Crews KR; Flerlage JE
Cancer Chemother Pharmacol; 2023 Jul; 92(1):1-6. PubMed ID: 37199744
[TBL] [Abstract][Full Text] [Related]
7. Isolated intracardiac recurrence of diffuse large B-cell lymphoma successfully treated with rituximab and bendamustine chemotherapy regimen.
Chang CH; Lin CS; Ho CL
J Postgrad Med; 2020; 66(3):176-177. PubMed ID: 32675458
[No Abstract] [Full Text] [Related]
8. Infections associated with bendamustine and anti-CD20 antibody in untreated follicular lymphoma: a real-world study.
Saburi M; Okuhiro K; Yoshida N; Haruyama T; Moroga Y; Yanai Y; Itani K; Takano K; Honda S; Ono K; Iwanaga M; Sasaki H; Abe M; Kohno K; Nakayama T; Ohtsuka E; Ogata M
J Clin Exp Hematop; 2023 Sep; 63(3):197-200. PubMed ID: 37518273
[No Abstract] [Full Text] [Related]
9. Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma.
Lu D; Lu T; Shi R; Gibiansky L; Agarwal P; Shemesh CS; Dere RC; Ogbu U; Hirata J; Chanu P; Girish S; Jin JY; Li C; Miles D
Pharm Res; 2020 Dec; 37(12):252. PubMed ID: 33258982
[TBL] [Abstract][Full Text] [Related]
10. Toxicities and Associated Factors in Patients Receiving Temozolomide-Containing Regimens: A 12-Year Analysis of Hospital Data.
Shi C; Wang X; Diao C; Zhu H; Yuan Q; Liu J; Li S; Gu M; Zhang Y
Drug Des Devel Ther; 2021; 15():2151-2159. PubMed ID: 34045849
[TBL] [Abstract][Full Text] [Related]
11. Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience.
Shotton R; Broadbent R; Alchawaf A; Mohamed MB; Gibb A; Martinez-Calle N; Fox CP; Bishton M; Pender A; Gleeson M; Cunningham D; Davies A; Yadollahi S; Eyre TA; Collins G; Djebbari F; Kassam S; Garland P; Watts E; Osborne W; Townsend W; Pocock R; Ahearne MJ; Miall F; Wang X; Linton KM
Blood Adv; 2024 Feb; 8(4):878-888. PubMed ID: 37967358
[TBL] [Abstract][Full Text] [Related]
12. A Canadian perspective on the safe administration of bendamustine and the prevention and management of adverse events.
Koolwine J; Crosbie T; Gazzé G; Turner R; Wiernikowski J; Assaily W
Curr Oncol; 2014 Feb; 21(1):35-42. PubMed ID: 24523603
[TBL] [Abstract][Full Text] [Related]
13. Infection risk and antimicrobial prophylaxis in bendamustine-treated patients with indolent non-Hodgkin lymphoma: An Australasian Lymphoma Alliance study.
Manos K; Churilov L; Grigg A; Di Ciaccio P; Wong J; Chandra Sekaran U; Wight J; Goh Z; Jina H; Butler L; Yannakou CK; Hamad N; Gregory GP; Gangatharan S; Cochrane T; Hawkes EA; Lasica M
Br J Haematol; 2024 Mar; ():. PubMed ID: 38485116
[TBL] [Abstract][Full Text] [Related]
14. Financial toxicity and its influencing factors in patients with non-Hodgkin lymphoma: A cross-sectional study.
Li T; Cui P; Shao M; Guo S; Zhang M; Chen C
Eur J Oncol Nurs; 2024 Jun; 70():102619. PubMed ID: 38797113
[TBL] [Abstract][Full Text] [Related]
15. Severe Liver Damage and Nonallergic Bronchitis with Eosinophilia in a Patient with Follicular Lymphoma Treated with Bendamustine plus Rituximab.
Jo T; Horio K
Case Rep Oncol; 2014 May; 7(2):497-502. PubMed ID: 25232317
[TBL] [Abstract][Full Text] [Related]
16. Considerations for anti-PD1-based first-line treatment of Hodgkin lymphoma.
Bröckelmann PJ
Br J Haematol; 2024 May; ():. PubMed ID: 38757338
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of tacrolimus in umbilical cord blood transplant patients focusing on the variation in red blood cell counts.
Yoshida S; Fujimoto A; Fukushima K; Ando M; Irie K; Hirano T; Miyasaka M; Shimomura Y; Ishikawa T; Ikesue H; Muroi N; Hashida T; Sugioka N
J Clin Pharm Ther; 2021 Feb; 46(1):190-197. PubMed ID: 33090593
[TBL] [Abstract][Full Text] [Related]
18. Safety evaluation of enzalutamide dose-escalation strategy in patients with castration-resistant prostate cancer.
Miura R; Hirabatake M; Irie K; Ikesue H; Muroi N; Kawakita M; Hashida T
Urol Oncol; 2021 Apr; 39(4):233.e15-233.e20. PubMed ID: 32988711
[TBL] [Abstract][Full Text] [Related]
19. Pharmacovigilance Evaluation of Bendamustine-related Skin Disorders using the Japanese Adverse Drug Event Report Database.
Uchida M; Kawashiri T; Maegawa N; Takano A; Hosohata K; Uesawa Y
J Pharm Pharm Sci; 2021; 24():16-22. PubMed ID: 33440131
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
